Last reviewed · How we verify
NCT04087148
Linear Growth of Children With Congenital Adrenal Hyperplasia
trial in Congenital Adrenal Hyperplasia in 60 participants. Status unknown.
24 October 2020
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 24 September 2019 |
| Primary completion | 24 October 2020 |
| Estimated completion | 24 October 2021 |
Conditions studied
- Congenital Adrenal Hyperplasia — all drugs for Congenital Adrenal Hyperplasia →
Sponsor
Assiut University
Who can join
Adults 1 to 18, any sex, with Congenital Adrenal Hyperplasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The congenital adrenal hyperplasias (CAHs) comprise a family of autosomal recessive disorders that disrupt adrenal steroidogenesis. Three specific enzyme deficiencies are associated with virilization of affected women. The most common form is 21-hydroxylase deficiency (21-OHD) due to mutations in the 21-hydroxylase (CYP21A2) gene. Other virilizing forms include 3b-hydroxysteroid dehydrogenase type 2 (HSD3B2) and 11b-hydroxylase deficiencies associated with mutations in the HSD3B2 and 11b-hydroxylase (CYP11B1) genes, respectively.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04087148
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Congenital Adrenal Hyperplasia
Currently open trials in the same condition.
- NCT07187375 — Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Le · Phase 2 · recruiting
- NCT06573723 — Institutional Registry of Rare Diseases · recruiting
- NCT05669950 — A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia · Phase 1, PHASE2 · recruiting
- NCT06754423 — Electronic Registry of Male Patients With Congenital Adrenal Hyperplasia 21-hydroxylase Deficiency · recruiting
- NCT04890444 — China Adrenal Disease Registry · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04087148 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 12 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04087148.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing